Health services research and advocacy in US cancer care: pathways from evidence to implementation.

Abstract

Although the gap between research and implementation is frequently emphasized, examples from United States (US) cancer care demonstrate that health services research can be translated into meaningful policy and practice. This Health Policy piece examines four US oncology cases spanning state legislation, federal payment reform, patient advocacy, and clinical measurement, which are the Delaware Cancer Consortium, the Oncology Care Model and Enhancing Oncology Model, COLONTOWN, and the COST financial toxicity measure. We assess how evidence moved into routine care through top-down policy and bottom-up community pathways. Across these cases, implementation has depended on sustained political and financial commitment, durable delivery mechanisms, data-driven evaluation, and collaboration among clinicians, policymakers, researchers, and patient advocates. These cases also illustrate limitations, which include administrative burden, financial toxicity, and uneven evidence of cost, quality, and equity outcomes. Some lessons of these cases include protected funding, navigation infrastructure, incentives centered around equity, patient and community engagement, and measurement that is linked to actionable interventions. Together, these examples show how health services research can influence cancer care when evidence is paired with appropriate policy mechanisms, financing structures, and implementation capacity.